Market News
4 min read | Updated on December 18, 2024, 14:47 IST
SUMMARY
Hamps Bio IPO allotment: The ₹6.22-crore Hamps Bio IPO was a fixed-price issue made up entirely of fresh issuance of 12.2 lakh shares with no offer-for-sale component. Shares were offered at ₹51 apiece in a lot size of 2,000 units.
For the financial year 2023-24, Hamps Bio posted a 16.4% increase in revenue to ₹6.5 crore compared with ₹5.6 crore in the previous financial year.
Hamps Bio IPO allotment: The investors, who had bid for the initial public offering (IPO) of small and medium enterprise (SME) Hamps Bio Ltd, expect the announcement of the share allotment status today, December 18.
The portion reserved for retail investors was overbid by more than 1,342 times, with bids received for 77.7 crore shares against 5.79 lakh shares on offer. Meanwhile, the non-institutional investors’ (NII) category was subscribed more than 758 times, with bids for 43.9 crore shares compared with 5.79 lakh shares reserved for the category.
If you were one of the investors in the issue, you can check the share allotment status online on the BSE website or at the web portal of the issue’s registrar, Bigshare Services Pvt. Ltd.
It’s important to note that the allotment details will be visible on the BSE and registrar websites only after the finalisation of share allocation by the company.
Successful bidders can expect the shares to be credited into their demat account by December 19, with refunds being initiated for the others the same day. The Hamps Bio stock is scheduled to list on the BSE SME on December 20.
Incorporated in 2007, Hamps Bio has strong brand presence in two core divisions -- pharmaceutical formulation and freeze-drying ingredient manufacturing and distribution.
The company is engaged in the marketing and distribution of pharmaceutical products under the “Hamps” brand like tablets, syrups, capsules, injectables, oil, and nutritional supplements. The FMCG division focuses on freeze-dried and frozen items under the “FzyEzy” brand including strawberry, jamun, mango, beet powder, chikoo powder etc.
The ₹6.22-crore Hamps Bio IPO was a fixed-price issue made up entirely of a fresh issuance of 12.2 lakh shares with no offer-for-sale component. Shares were offered at ₹51 apiece in a lot size of 2,000 units.
The company had appointed Marwadi Chandarana Intermediaries Brokers Pvt. Ltd as the book-running lead manager of the issue. Bigshare Services Pvt. Ltd was the registrar, while Pure Broking was the market maker for the IPO.
Hamps Bio said that the company intended to use the proceeds from the fresh issue for purchase of plant and machinery for the FMCG division, enhancing the visibility and awareness of the brand and for general corporate purposes.
For the financial year 2023-24, Hamps Bio posted a 16.4% increase in revenue to ₹6.5 crore compared with ₹5.6 crore in the previous financial year. Profit after tax (PAT) rose by 39.5% to ₹50.07 lakh in FY24 compared with ₹35.90 lakh in FY23.
The promoters of Hamps Bio are Herrik Shah, Shrenik Shah, Pallavi Shah, Mitali Shah, Herrik Shah HUF and Shrenik Shah HUF.
Shareholding pre-issue | 100% |
---|---|
Shareholding post-issue | 71.99% |
About The Author
Next Story